BR112015008924A2 - combinação - Google Patents
combinaçãoInfo
- Publication number
- BR112015008924A2 BR112015008924A2 BR112015008924A BR112015008924A BR112015008924A2 BR 112015008924 A2 BR112015008924 A2 BR 112015008924A2 BR 112015008924 A BR112015008924 A BR 112015008924A BR 112015008924 A BR112015008924 A BR 112015008924A BR 112015008924 A2 BR112015008924 A2 BR 112015008924A2
- Authority
- BR
- Brazil
- Prior art keywords
- chloro
- methyl
- ethyl
- amino
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 abstract 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716780P | 2012-10-22 | 2012-10-22 | |
| PCT/US2013/065827 WO2014066202A1 (en) | 2012-10-22 | 2013-10-21 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008924A2 true BR112015008924A2 (pt) | 2017-07-04 |
Family
ID=50545138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008924A BR112015008924A2 (pt) | 2012-10-22 | 2013-10-21 | combinação |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150272952A1 (enExample) |
| EP (1) | EP2908815A4 (enExample) |
| JP (1) | JP2015534986A (enExample) |
| KR (1) | KR20150074097A (enExample) |
| CN (1) | CN104902899A (enExample) |
| AU (1) | AU2013334943A1 (enExample) |
| BR (1) | BR112015008924A2 (enExample) |
| CA (1) | CA2889051A1 (enExample) |
| IN (1) | IN2015DN03909A (enExample) |
| MX (1) | MX2015005113A (enExample) |
| RU (1) | RU2015119245A (enExample) |
| WO (1) | WO2014066202A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EA022982B1 (ru) * | 2009-10-08 | 2016-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация для лечения рака или предраковых синдромов |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
| US20130072507A1 (en) * | 2010-05-21 | 2013-03-21 | Glaxosmithkline Llc | Combination |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
-
2013
- 2013-10-21 IN IN3909DEN2015 patent/IN2015DN03909A/en unknown
- 2013-10-21 US US14/437,297 patent/US20150272952A1/en not_active Abandoned
- 2013-10-21 CN CN201380067522.7A patent/CN104902899A/zh active Pending
- 2013-10-21 AU AU2013334943A patent/AU2013334943A1/en not_active Abandoned
- 2013-10-21 RU RU2015119245A patent/RU2015119245A/ru not_active Application Discontinuation
- 2013-10-21 JP JP2015538098A patent/JP2015534986A/ja active Pending
- 2013-10-21 EP EP13848997.6A patent/EP2908815A4/en not_active Withdrawn
- 2013-10-21 KR KR1020157013079A patent/KR20150074097A/ko not_active Withdrawn
- 2013-10-21 BR BR112015008924A patent/BR112015008924A2/pt not_active IP Right Cessation
- 2013-10-21 WO PCT/US2013/065827 patent/WO2014066202A1/en not_active Ceased
- 2013-10-21 MX MX2015005113A patent/MX2015005113A/es unknown
- 2013-10-21 CA CA2889051A patent/CA2889051A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150272952A1 (en) | 2015-10-01 |
| AU2013334943A1 (en) | 2015-05-14 |
| IN2015DN03909A (enExample) | 2015-10-02 |
| MX2015005113A (es) | 2015-10-29 |
| EP2908815A1 (en) | 2015-08-26 |
| JP2015534986A (ja) | 2015-12-07 |
| EP2908815A4 (en) | 2016-06-22 |
| WO2014066202A1 (en) | 2014-05-01 |
| CN104902899A (zh) | 2015-09-09 |
| RU2015119245A (ru) | 2016-12-10 |
| CA2889051A1 (en) | 2014-05-01 |
| KR20150074097A (ko) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210171A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| IN2015DN03219A (enExample) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| MX2014011270A (es) | Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r. | |
| MX2013008074A (es) | Combinacion. | |
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| BR112012008271A2 (pt) | combinação | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| BR112014002361A2 (pt) | método para tratamento de câncer pelo uso combinado de fármacos | |
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25B | Requested transfer of rights rejected |
Owner name: GLAXOSMITHKLINE LLC (US) |